The present disclosure relates to compounds of formula (I) wherein R1 represents phenyl or monocyclic heteroaryl optionally substituted by one, two or three R3; r2 represents an
aryl or heteroaryl group optionally substituted by one, two or three R6 groups; each R3 is independently selected from the group consisting of
halogen, cyano, (C1-C4)
alkyl, or (C1-C4) alkoxy; r4 and R5 are independently selected from
halogen, (C1-C4)
alkyl, (C1-C4) alkoxy, or R4 and R5 together form a (C1-C4) alkylene bridge; m and s are independently 0 or 1; p, q, r and t are independently 0 or 1; each R6 is independently selected from the group consisting of
halogen, cyano,-NH2 group,-OH, (C1-C4)
alkyl,-CF3,-C (O) NH2,-C (O) NH-(C1-C4) alkyl,-C (O) OH,-C (O) O-(C1-C4) alkyl,-SO2NH2, (C1-C4) alkoxy,-O-(C1-C4) alkylene-(C3-C6) cycloalkyl,-O-(C3-C6) cycloalkyl,-O-(C3-C6) heterocycloalkyl, (C3-C6) heterocycloalkyl, heteroaryl, and pendant
oxygen groups; or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. The present disclosure further relates to pharmaceutical compositions containing said novel compounds.